Treatment with low-dose IM versus SC + IV insulin

Onur et al, 197951110 children with a history of diabetic ketoacidosis who had signs of ketoacidosis (pH < 7.35 or bicarbonate < 15 mEq/l)
Aged 4–15 years
  1. IM 0.1 units/kg soluble insulin every 2 hours
  2. 0.1 units/kg soluble insulin, half give SC and half IV every 4 hours
Time to achieve serum glucose < 250 mg/dl
Immunoreactive glucagon concentration
Time to achieve serum glucose < 250 mg/dl was 5.3 ± 0.7 hours in the conventionally treated group and 7.1 ± 0.6 hours in the low- dose IM group. This is approximately 50% longer in the low-dose IM group to reach the same control, but this was not statistically significantly different
To achieve serum glucose < 250 mg/dl, total insulin required was 1.2 ± 0.2 units/kg in the conventionally treated group and 0.4 ± 0.1 units/kg in the low-dose IM group. This was statistically significantly different, p < 0.001. No significant difference in IV fluids given during this time
No difference in the immunoreactive glucagon concentration between the two groups when serum glucose was 250 mg/dl
Not randomisedControlled trial (alternate allocation)IIa

From: Evidence tables

Cover of Type 1 Diabetes
Type 1 Diabetes: Diagnosis and Management of Type 1 Diabetes in Children and Young People.
NICE Clinical Guidelines, No. 15.2.
National Collaborating Centre for Women's and Children's Health (UK).
London: RCOG Press; 2004 Sep.
Copyright © 2004, National Collaborating Centre for Women’s and Children’s Health.

Apart from any fair dealing for the purposes of research or private study, criticism or review, as permitted under the Copyright, Designs and Patents Act, 1988, no part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

The rights of National Collaborating Centre for Women’s and Children’s Health to be identified as Author of this work have been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.